Akari Therapeutics Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated April 29, 2019, is a report of a foreign private issuer filed by Akari Therapeutics Plc. The filing serves as a supplement to a previous Form 6-K dated April 26, 2019, regarding a scientific presentation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on a scientific update and contains no financial statements or metrics.
Material Changes
There are no material financial changes reported. The primary update is the presentation of a poster on April 28, 2019, at the Association for Research in Vision and Ophthalmology annual meeting in Vancouver. The presentation, titled "Targeting the leukotriene B4 pathway and/or complement C5 via dual-functional recombinant coversin (nomacopan) in Experimental Autoimmune Uveitis (EAU)," details research on the company's drug candidate, nomacopan.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or a discussion of risks and contingencies. The content is limited to the announcement of the scientific poster presentation and the attachment of the poster as Exhibit 99.1.
Key Facts for Investors
- The company presented new data on April 28, 2019, regarding nomacopan in the context of Experimental Autoimmune Uveitis (EAU).
- The research targets the leukotriene B4 pathway and/or complement C5.
- The filing was signed by Clive Richardson, Interim Chief Executive Officer and Chief Operating Officer.
- No financial data or operational metrics are included in this specific filing.